Automate Your Wheel Strategy on DXCM
With Tiblio's Option Bot, you can configure your own wheel strategy including DXCM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DXCM
- Rev/Share 12.0559
- Book/Share 7.1011
- PB 10.3167
- Debt/Equity 0.5061
- CurrentRatio 1.8825
- ROIC 0.1661
- MktCap 28572591647.0
- FreeCF/Share 2.7856
- PFCF 26.5249
- PE 33.875
- Debt/Assets 0.2192
- DivYield 0
- ROE 0.3244
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 3
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | DXCM | Barclays | Equal Weight | Underweight | -- | $71 | Jan. 12, 2026 |
| Upgrade | DXCM | Morgan Stanley | Equal Weight | Overweight | -- | $75 | Dec. 2, 2025 |
| Initiation | DXCM | Evercore ISI | -- | In-line | -- | $68 | Nov. 25, 2025 |
| Resumed | DXCM | Stifel | -- | Buy | -- | $85 | Oct. 21, 2025 |
| Downgrade | DXCM | Oppenheimer | Outperform | Perform | -- | -- | Sept. 8, 2025 |
| Initiation | DXCM | Argus | -- | Buy | -- | $100 | Aug. 21, 2025 |
| Initiation | DXCM | Truist | -- | Buy | -- | $102 | June 16, 2025 |
| Initiation | DXCM | Goldman | -- | Buy | -- | $104 | May 30, 2025 |
| Initiation | DXCM | Mizuho | -- | Outperform | -- | $85 | April 10, 2025 |
| Upgrade | DXCM | Redburn Atlantic | Neutral | Buy | $85 | $115 | Feb. 3, 2025 |
News
Is Dexcom Stock A Buy Now?
Published: November 03, 2025 by: Forbes
Sentiment: Neutral
DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from which it has bounced significantly in the past.
Read More
DexCom Stock Falls Despite Q3 Earnings Beat, 2025 Revenue View Raised
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Positive
DXCM posts double-digit Q3 growth and raises 2025 revenue outlook, but shares tumble despite strong CGM momentum and innovation updates.
Read More
DXCM Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against DexCom, Inc.
Published: October 31, 2025 by: Business Wire
Sentiment: Neutral
RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of those who purchased or otherwise acquired DexCom securities between July 26, 2024, and September 17, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is December 26, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered DexCom losses,.
Read More
DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: October 31, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 31, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against DexCom, Inc. ("DexCom" or "the Company") (NASDAQ: DXCM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired DexCom securities between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period").
Read More
Shareholders who lost money in shares of DexCom, Inc. (NASDAQ: DXCM) Should Contact Wolf Haldenstein Immediately
Published: October 31, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a federal securities class action lawsuit has been filed against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) and certain of its officers for alleged violations of federal securities laws. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Class Period: July 26, 2024 – September 17, 2025 (inclusive) The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and failed to disclose that: DexCom made material design changes to its G6 and G7 continuous …
Read More
DexCom Stock Is the Worst Performer in the S&P 500. Here's Why.
Published: October 31, 2025 by: Barrons
Sentiment: Negative
The maker of diabetes technology posts better-than-expected revenue but shares are falling.
Read More
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit
Published: October 28, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
Read More
Rosen Law Firm Urges DexCom, Inc. (NASDAQ: DXCM) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Published: October 28, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of DexCom, Inc. (NASDAQ: DXCM) securities between July 26, 2024 and September 17, 2025, both dates inclusive (the “Class Period”). DexCom is a medical device company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Alleg.
Read More
Portnoy Law Firm Announces Class Action on Behalf of DexCom, Inc. Investors
Published: October 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 28, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises DexCom, Inc., (“DexCom” or the "Company") (NASDAQ: DXCM) investors off a class action on behalf of investors that bought securities between July 26, 2024 and September 17, 2025, inclusive (the “Class Period”). DexCom investors have until December 26, 2025 to file a lead plaintiff motion.
Read More
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed DexCom, Inc. (DXCM)
Published: October 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) securities between July 26, 2024 and September 17, 2025, inclusive (the “Class Period”).
Read More
Can Dexcom Deliver Strong Q3 Earnings on Stelo Gains and G7 Adoption?
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
DXCM's Q3 results are likely to benefit from rising G7 use, early Stelo traction and expanding access across Type 2 diabetes markets.
Read More
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of DexCom, Inc. (DXCM) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Published: October 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Oct. 28, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information, including allegations that: (i) DexCom had made material design changes to the G6 and G7 unauthorized by the United States Food and Drug Administration (the "FDA"); (ii) the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (iii) …
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc. - DXCM
Published: October 23, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc. - DXCM
Published: October 13, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc. - DXCM
Published: October 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Kuehn Law Encourages Investors of DexCom, Inc. to Contact Law Firm
Published: September 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc. - DXCM
Published: September 23, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM).
Read More
Kuehn Law Encourages Investors of DexCom, Inc. to Contact Law Firm
Published: September 19, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 19, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders.
Read More
Kuehn Law Encourages Investors of DexCom, Inc. to Contact Law Firm
Published: September 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 11, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders.
Read More
Investing in the Age of Longevity: Silver Economy Stocks in Focus
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.
Read More
Why Is DexCom (DXCM) Down 7% Since Last Earnings Report?
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Negative
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock?
Read More
DexCom Expands Access and Innovation While Balancing Headwinds
Published: August 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
DXCM grows on type 2 access, Stelo adoption, and new sensor launches, but faces margin pressures, competition and leadership transition.
Read More
Dexcom's Arizona facility can service good portion of U.S. business, says CEO
Published: August 05, 2025 by: CNBC Television
Sentiment: Positive
CNBC's "The Exchange" team discusses the potential of tariffs on pharmaceuticals, U.S. manufacturing and more with Dexcom CEO and chairman Kevin Sayer.
Read More
DexCom Stock Falls Despite Q2 Earnings Beat & 2025 Sales View Raise
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
DXCM beats on Q2 earnings and raises 2025 sales guidance, but shares dip as margin pressure dampens investor enthusiasm.
Read More
Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
DexCom Q2 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.
Read More
DexCom: Delivering Consistent Growth
Published: July 21, 2025 by: Seeking Alpha
Sentiment: Positive
DexCom focuses on continuous glucose monitoring systems, with a strong market position and global reach. Q1 results showed 13% revenue growth, beating expectations, though earnings were slightly below consensus. Analysts remain bullish, with most issuing Buy ratings and price targets ranging from $87 to $110 per share.
Read More
Are Medical Stocks Lagging DexCom (DXCM) This Year?
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how DexCom (DXCM) and Amarin (AMRN) have performed compared to their sector so far this year.
Read More
Why This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 Years
Published: July 20, 2025 by: The Motley Fool
Sentiment: Negative
Medical device specialist DexCom (DXCM -0.33%) has encountered significant headwinds in the past year. The company's financial results haven't been quite up to the market's standards, and broader market volatility caused by President Donald Trump's trade policies isn't helping either.
Read More
Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews
Published: July 17, 2025 by: Business Wire
Sentiment: Neutral
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes. This year's Dexcom U roster welcomes 13 new athletes from colleges and universities across the country — including the University of Oregon, San Diego State University, and Northwestern University — representing 12 sports suc.
Read More
DexCom (DXCM) Upgraded to Strong Buy: Here's What You Should Know
Published: July 14, 2025 by: Zacks Investment Research
Sentiment: Positive
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
About DexCom, Inc. (DXCM)
- IPO Date 2005-04-14
- Website https://www.dexcom.com
- Industry Medical - Devices
- CEO Jacob Steven Leach
- Employees 10200